• NFX-21

    It is now known nuclear receptor farnesoid X receptor (FXR) is a key regulator of bile acid (BA) metabolism in the liver. Additionally, FXR regulates lipid metabolism, insulin sensitivity, and energy homeostasis and its activation lowers plasma and liver triglycerides.

    Learn More »

  • Technology

    Nectid has a screening platform that utilizes existing knowledge- scientific art, patent databases, published clinical trial information, published bioassays, protein expressions to design new platform technologies with better clinical profiles than known drugs, and to identify newer use for known GRAS ingredients.

    Learn More »

  • Pipeline

    Diseases such cancer, neurodegenerative disorders glaucoma and diabetes are all complex multidimensional disorders and they require modulation of multiple pathways. Nectid has a deeper and wider pipeline.

    Learn More »

  • Intellectual Properties

    Nectid views its intellectual properties are critical in protecting its investments and in finding a marketing partner to license these drugs. Nectid currently has over 50 patent applications.

    Learn More »

  • About Us

    The company has demonstrated capability to conceptualize, design, and secure intellectual properties for key therapeutic markets. The 21 patent applications have been acquired by companies like Grunenthal, Tamasek etc.

    Learn More »

Welcome to Nectid
Nectid is a privately held drug discovery and nutritional technology development company. The focus is on discovering products and platforms that meet the unmet needs of healthcare needs. Nectid, founded by industry professionals and scientists, has operations in Princeton, NJ and developmental operations out of India. Nectid leverages the critical product designing skills from US with the technical capabilities in India to develop first-in-class novel patentable products and platform technologies.
Key Projects
BrainWhey© is a novel proprietary patent pending platform technology formulated with three GRAS ingredients that have been in nutritional use for decades. The formulation is unique because of its ability to preserve the stability of Omega-3 in fortified foods against peroxidation and preserve against odor deterioration on a retail shelf.

Nectidís meltonergic platform involves a combination of GRAS ingredient with melatonergic agonist for Autism Spectrum Disorders (ASD) and Multiple Sclerosis.

LiveDHA is a novel proprietary patent pending platform technology formulated with DHA and Capsaicin for liver support. Capsaicin is in dietary use for several hundreds of years. Capsaicin acts its receptor, transient receptor potential vanilloid 1 (TRPV1) a cation channel implicated in several liver dysfunctions. DHA is known to act on bile acid receptor (BAR), also known as farnesoid X receptor (FXR). This LivDHA is expected to provide support for liver health.